NCT04886063View on ClinicalTrials.gov

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

423

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

October 23, 2024

Study Completion Date

October 23, 2024

Conditions
Alzheimer Disease
Interventions
DRUG

ATH-1017

Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

Trial Locations (1)

14620

University of Rochester-AD-CARE Program, Rochester

Sponsors

Lead Sponsor

Athira Pharma
All Listed Sponsors
lead

Athira Pharma

INDUSTRY

NCT04886063 - Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter